Institutional investors purchased a net $4.5 million shares of IMMU during the quarter ended December 2012, and now own 39.86% of the total float, a percentage that is typical for companies in the Biotechnology industry.
| Individual stakeholders | 6.34% |
| Mutual fund holders | 24.77% |
| Other institutional | 15.10% |